Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of ...
Cingulate Inc. (NASDAQ:CING) is one of the best NASDAQ growth stocks to buy and hold forever. On March 18, Cingulate reported its financial results for Q4 and the full year 2025, highlighting the ...
Hosted on MSN
CING: Laying the foundation for 1H:27 launch
Cingulate, Inc. (NASDAQ: CING) reported 2025 results on March 18 th, 2026. The company generated no revenue and recorded operating expense of $20.0 million. The new drug application (NDA) submitted to ...
Cingulate Inc. has been granted a European patent for its ADHD treatment, CTx-1301. Following the patent news, Cingulate's stock has surged by 302.9%, reflecting strong market confidence in the ...
Cingulate Inc CING shares are trading lower after the company priced its $4-million public offering at around 58 cents per share and accompanying warrants. The offering includes 6.93 million shares ...
An unnamed feeling sets in around your mid-20s, perpetually itching the back of your brain as if someone scraped out the soft nub of your visual cortex and replaced it with the crunchy Styrofoam from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results